Horizon’s specialty drugs grew 11 percent in the quarter, accounting for 70 percent of the drugmaker’s $320 million in net sales. Meanwhile, inflammation drug sales slumped 8 percent compared with the same period a year earlier.
*License and supply agreement amended. Known as Rayos in U.S. **Divested in June 2019.